233 results on '"Göke, R."'
Search Results
2. Krebsvorbeugung und -vorsorge bei Diabetespatienten
3. The Rap–B-Raf signalling pathway is activated by glucose and glucagon-like peptide-1 in human islet cells
4. Flavone initiates a hierarchical activation of the caspase-cascade in colon cancer cells
5. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)
6. Autorenverzeichnis
7. Apudome: Neuroendokrine Tumoren des Gastrointestinaltrakts
8. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
9. Neuroendocrine Gastro-Entero-Pancreatic (GEP) Tumors
10. Apudome: Neuroendokrine Tumoren des Gastrointestinaltrakts
11. Atrial natriuretic factor has a weak insulinotropic action in the isolated perfused rat pancreas
12. In vitro Evaluation of an Enhanced Human Serum Amyloid A (SAA2) Promoter-Regulated Soluble TNF Receptor Fusion Protein for Anti-Inflammatory Gene Therapy
13. Physiology and Pathophysiology of GLP-1
14. The signal transduction of the glucagon-like peptide 1 receptor: fishing beyond the protein kinase level
15. Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
16. Characteristics of high‐ and low‐risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
17. Characteristics of high- and low-risk individuals in the PRIORITY study:urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
18. Effect of a low-molecular weight serine proteinase inhibitor (camostate) on amylase release from isolated pancreatic acini
19. Internalization of glucagon-like peptide-1(7–36)amide in rat insulinoma cells
20. Influence of a low molecular weight serine proteinase inhibitor (camostate) on lipolysis of isolated adipocytes
21. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial
22. A dynamic interaction between GTPases ras and rap determines signaling in beta-cells
23. Das programmed cell death protein 4 (pdcd4) wirkt in neuroendokrinen Tumorzellen als Tumorsuppressorgen
24. Adäquat gleichmäßige Senkung des Nüchtern- und postprandialen Blutzuckers über alle Mahlzeiten nach 1xig morgendlicher Gabe von Lixisenatid zum Basalinsulin in der täglichen Praxis
25. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany
26. Vildagliptin ist Sitagliptin in der Senkung der Nüchternglukose überlegen: Ergebnisse einer randomisierten kontrollierten Cross-Over Studie
27. Basalinsulin plus Lixisenatid versus Basal-Bolus Therapie (ICT) und koventionelle Therapie (CT) bei Patienten mit Typ 2 Diabetes - Ergebnisse eines indirekten Vergleichs
28. Intestinal effects of α-glucosidase inhibitors: absorption of nutrients and enterohormonal changes
29. Molecular cloning of a cDNA encoding for the GLP-1 receptor expressed in rat lung
30. Biological actions of glucagon-like peptide(GLP)-2 revealed — how pluripotential is the glucagon gene?
31. The genomic organization of the human GLP-1 receptor gene
32. Rap/B-Raf signal transduction is activated in neuroendocrine tumors of the digestive tract and may be effectively inhibited by Raf-kinase inhibitors
33. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21Waf1/Cip1
34. Programmed cell death protein 4 suppresses CDK–1/cdc 2 via induction of p21Waf1/Cip1
35. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumour disease
36. Onkogenetischen Rolle des Rap/B-Raf Signaltransduktionsweges in neuroendokrinen Tumoren
37. Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II
38. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4
39. Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary
40. Distribution of GLP-I binding sites in the rat brain: evidence that Exendin-4 is a ligand of brain DLP-1 binding sites
41. Glucagon-like peptide 1: on its way to clinical application
42. Specific calcitonin gene-related peptide binding sites present throughout rat intestine
43. Neuropeptide Y2 receptors on nerve endings from the rat neurohypophysis regulate vasopressin and oxytocin release
44. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
45. Amylin alters the biological action of the incretin hormone GLP-1(7-36)amide
46. Light- and electronmicroscopic investigations of glucagon-like peptide 1 immunoreactivity in gastroenteropancreatic endocrine tumors
47. Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
48. Glucagon-like peptide-1(7–36) amide is a new incretin/enterogastrone candidate
49. CCK Receptor Antagonist Loxiglumide Alters Uptake of CCK in Perfused Liver and Pancreatic Acini of the Rat
50. The effects of two FMRFamide related peptides (A-18-F-amide and F-8-F-amide; ‘morphine modulating peptides’) on the endocrine and exocrine rat pancreas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.